Citius Oncology Announces Positive Phase 1 LYMPHIR Data

Citius Oncology ( (CTOR) ) has issued an announcement.

On March 4, 2026, Citius Oncology reported positive topline safety and efficacy data from an investigator-initiated Phase 1 trial of LYMPHIR administered before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma patients. The study, led by investigators at the University of Minnesota and City of Hope, aimed to enhance standard lymphodepletion by using LYMPHIR to deplete regulatory T-cells ahead of CAR-T infusion.

All 14 enrolled patients completed LYMPHIR dosing and proceeded to CAR-T treatment, with the regimen showing no dose-limiting toxicities and no Grade 3 or higher LYMPHIR-related immune adverse events or infusion reactions. Investigators reported effective Treg depletion in nearly all participants and an 86% overall response rate at one month, including 57% complete and 29% partial responses, alongside one-year progression-free and overall survival rates of 77% and 84%, respectively.

Adverse events associated with LYMPHIR, such as low-grade capillary leak syndrome, fever and transient liver enzyme elevations, were described as manageable, while higher-grade cytopenias aligned with expected lymphodepletion effects and CAR-T-related toxicities were limited to low-grade cytokine release syndrome and neurotoxicity. While the Phase 1 trial was not designed or powered to determine definitive efficacy or long-term comparative outcomes, the data bolster Citius Oncology’s strategy to position LYMPHIR as an immunomodulatory adjunct to existing cancer therapies, potentially expanding its role beyond its current CTCL indication and reinforcing the company’s footprint in the immuno-oncology market.

The most recent analyst rating on (CTOR) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Spark’s Take on CTOR Stock

According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.

The score is primarily weighed down by weak financial performance (pre-revenue, widening losses, and increasing cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate events—commercial launch of LYMPHIR and added funding—provide support but do not fully offset profitability and financing risks.

To see Spark’s full report on CTOR stock, click here.

More about Citius Oncology

Citius Oncology, Inc. is an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc., developing and commercializing targeted cancer therapies. The Nasdaq-listed firm launched LYMPHIR in the U.S. in December 2025 for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma and estimates an initial, underserved market opportunity exceeding $400 million.

The company’s competitive positioning is underpinned by orphan drug status, complex manufacturing technology, trade secrets and pending patents supporting immuno-oncology uses, including combination regimens. Citius Oncology’s strategy centers on leveraging LYMPHIR’s immunomodulatory properties and exploring its use alongside other approved therapies to enhance anti-tumor immune responses in difficult-to-treat cancers.

Average Trading Volume: 318,139

Technical Sentiment Signal: Sell

Current Market Cap: $93.57M

Learn more about CTOR stock on TipRanks’ Stock Analysis page.